Факторы апоптоза и пролиферации при раке почки

1. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2004 году. М.; 2005.

2. Mathew A., Devesa S.S., Fraumeni J.F. Jr. et al. Global increases in kidney cancer incidence, 1973–92. Eur J Cancer Prev 2002;11:171–8.

3. Flanigan R.C., Campbell S.C., Clark J.I. et al. Metastatic renal cell carcinoma. Current treatment options. Oncology 2003;4:385–90.

4. Mickisch G.H. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Eur Urol 2003;43:670–9.

5. Linechan S.H., Shipley W.U., Parkinson D.R. Cancer of the kidney and ureter. In: De Vita V.T. Ir., Ed. Cancer: principles and practice of oncology, 4th ed. Philadelphia, J.B. Lippincot; 1993.

6. Гарин А.М., Хлебнов А.В. Справочник практической химиотерапии опухолей. М., Росмэн; 1995.

7. Amato R.J. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177–86.

8. Fossa S., Droz J.P., Pavone-Macaluso M. et al. Vinblastine in Metastatic Renal Cell Carcinoma: EORTC Phase III Trial 30882. Eur J Cancer 1992;28a:878–80.

9. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.

10. Pyrhönen S., Salminen E., Ruutu M. et al. Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Carcinoma. J Clin Oncol 1999;17:2859–70.

11. Steiner G., Strander H., Carbin B.E. et al. Recombinante interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomised trial. Acta Oncol 1990;29:155.

12. Papac R.J., Keohane M.F. Hormonal therapy for metastatic renal cell carcinoma combined androgent and prover followed by high dose tamoxifen. Eur J Cancer 1993;29:997–9.

13. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient followup. Radiother Oncol 1999;52:111–21.

14. Huguenin P.U., Kieser S., Glanzmann C. et al. Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points. Int J Rad Oncol Biol Phys 1998;41:401–5.

15. Tretter C.P.G., Ernstoff M.S. Chemotherapy, Hormonal therapy, and Interferons. Genitourinary Oncology, 2nd ed. Edited by N.J. Vogelzang, P.T. Scarding, W.U. Shipley, D.S. Coffey. USA, Lippincott Williams and Wilkins; 1999. p. 248–59.

16. Kim H.L., Seligson D., Liu X. et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;73(5):1496–501.

17. Vasavada S.P., Novick A.C., Williams B.R. P53, Bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51:1057–61.

18. Uzunlar A.K., Sahin H., Yilmaz F. et al. Expression of p53 oncoprotein and Bcl-2 in renal cell carcinoma. Saudi Med J 2005;26:37–41.

19. Cho D.S., Joo H.J., Oh D.K. et al. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 2005;46(1):133–40.